Out-Licensing Lessons: How to Put Your Best Foot Forward
In this short webinar, our experts talk through some of the issues you need to focus on as you plan each stage of your journey to commercial success. We’ll ask: How do you optimise outreach activities? How can you prepare for stringent due diligence activities? How can you maximise optionality in dealmaking negotiations? What are […]
Under Pressure: The State of Biopharma in Q1 2025
The unpredictability of the pharmaceutical market continued in the first quarter of 2025 with geopolitics and uncertainty keeping pharma players of all sizes under pressure. To help you stay on top of all the changes, our latest quarterly report provides analysis of the highlights – and lowlights – of the opening three months of the […]
Going Solo – Biotech Commercialization
In 2024, biotechs were behind almost two-thirds of the FDA’s new drug approvals. Many biotechs are choosing to commercialize their products themselves, rather than partnering with Big Pharma players. Many fail, but some things have turned in biotech’s favor. In this report, we look at the market dynamics that are enabling biotechs to go to […]
Building Beyond Orphans
How critical is orphan designation to a biotech working towards bringing a new therapy to market? There are significant financial benefits associated with orphan designation that can help a small company to keep the lights on during the development process. So what happens to a company’s orphan drugs strategy when that designation is taken away? […]
Going Solo: What’s Driving the Biotech Boost?
What are the tailwinds on the commercial battlefield for biotechs? How can you retain company culture right up to launch? How can smaller companies set themselves up to win against the biggest players?
Biotech Sponsors Dominate 2024 FDA Approvals
Biotech sponsors accounted for almost two thirds of FDA approvals in 2024 – a significant shift from the prior year, when big or mid-sized pharma names sat behind just over half of approvals. This “biotech boost” isn’t all driven by rare diseases, with several big disease areas receiving new entrants from smaller players. In this […]
2025 Preview
Key discussion points: Are GLP-1s still dominating the top 10? What does that mean for the leading companies in 2025? Where are the most valuable pipeline products emerging? Which therapy areas and new drugs are likely to drive growth? Are we finally set for a return to dealmaking? And what impact could the new Trump […]
Evaluating: Portfolio Biotechs
Portfolio-style biotechs look attractive in what remains a risk-shy, cash-conserving and unpredictable environment. The efficient and flexible model – comprising R&D-focused subsidiaries or ‘spokes’ led by a central hub – offers investors a way to spread asset-risk across a trusted central management team. It’s not a new model, the oldest hub-and-spoke are over a decade […]
From Trials to Take Off: The Road to Launch Excellence
Get expert guidance on how to: Stay ahead of industry best practices for transitioning products from Phase III to launch. Improve your forecasting skills and resource management, directly impacting your product’s market success. Leverage data more effectively to enhance decision-making and profitability throughout the product lifecycle.
Out-Licencing Strategies: How to Secure the Right Partner
When a biotech or biopharma’s flagship asset is ready for out-licensing, which strategies will get it noticed by the right partners? To gain the attention of larger players, companies need to present clear evidence of their asset’s efficacy and market potential, along with a realistic understanding of the types of deals they can secure. Leveraging […]
